The mRNA Cancer Vaccine: The Dawn of Personalised Oncology
The Beginning of a New Cancer Industry

The financial implications are enormous. Analysts have estimated that an approved personalised melanoma vaccine could generate more than $6 billion in annual sales in melanoma alone, with considerably greater potential if the technology succeeds against other cancers.
Investors reacted accordingly. On August 19, Moderna’s shares surged as much as 160%, adding tens of billions of dollars to the company’s market value. Merck’s shares also jumped sharply.
But the real value of intismeran cannot be measured only in stock prices.
For more than a century, researchers have tried to teach the immune system to fight cancer. The problem was always the same: cancer is part of the body, and identifying exactly what the immune system should attack is extraordinarily difficult.
mRNA technology has offered a new answer. Read the tumour. Identify its mutations. Build the vaccine. Train the immune system.
The Phase 3 result from Merck and Moderna shows that this sequence can work at scale.
Melanoma may be the first major proof. The much larger question is what happens when the same idea is applied to every cancer that carries its own distinctive genetic signature.
If personalised oncology follows the trajectory that this breakthrough suggests, the future of cancer treatment may increasingly begin with a patient’s tumour being sequenced—and end with a vaccine made for that one person.